Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 8/20 | 0.53 |
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231817 | 0.91 | DRD2 (0.50) | DRD4DRD2SMN1; SMN2 | |
| SCHEMBL3226346 | 0.91 | DRD2 (0.50) | DRD4DRD2SMN1; SMN2 | |
| SCHEMBL3226458 | 0.89 | SIGMAR1 (0.52) | KCNH2DRD4DRD2KDM4ECACNA1G | |
| SCHEMBL3229075 | 0.88 | DRD2 (0.51) | DRD4DRD2KDM4EHTR1A | |
| SCHEMBL3226486 | 0.87 | SIGMAR1 (0.48) | KCNH2DRD4DRD2MAPTTSHR | |
| SCHEMBL3228750 | 0.86 | HSD17B10 (0.51) | KCNH2DRD4DRD2SMN1; SMN2MAPT | |
| SCHEMBL3235866 | 0.85 | HTR7 (0.51) | KCNH2DRD4DRD2HTR1A | |
| SCHEMBL3227450 | 0.85 | SIGMAR1 (0.46) | DRD4DRD2KDM4EHTR1A | |
| SCHEMBL3237665 | 0.85 | SIGMAR1 (0.55) | DRD4DRD2KDM4EHTR1A | |
| SCHEMBL3231452 | 0.84 | DRD2 (0.44) | DRD4DRD2KDM4ECACNA1GHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236806-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-07 | — | — | US | claimed |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | KCNH2 1834/4885DRD4 7/4885DRD2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.